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A Pilot Study of Diabetes Management in the Managed Care Setting
Rachel Wagman, MD, Resident Department of Internal Medicine 1997-2000
and Michael Steinberg, MD, MPH
Introduction
Diabetes mellitus represents a disease entity that primary
care providers commonly encounter in the outpatient setting. Patient visits encompass a broad range of concerns,
from optimizing management of hyperglycemia to the
sequelae of chronic disease. The third National Health
and Nutrition Exam Survey (NHANES III) 1988-1994
has reported the prevalence of diabetes mellitus type 2 in
1
the U.S adult population at 12.3% . The cost of diabetes
2
in 1998, estimated at $77 billion , is a formidable challenge to the health care community and third-party payers. Historically, Health Maintenance Organizations
(HMOs) have encouraged more preventative tests, procedures, and exams to curtail the development of chronic
3
disease than indemnity plans . The influx of patients of
all ages into these capitated plans has spurred such organizations to reconcile cost-conscious initiatives with the
expense of chronic disease using treatment algorithms.
Aetna U.S. Healthcare (USHC) has developed Healthy
Outlook Programs to manage patients with diabetes using
patient education, treatment recommendations, and a
U.S. Quality Algorithm (USQA) Diabetes Performance
4
Report for providers . It is not clear whether this program has helped patients with Type 2 diabetes achieve
improved glycemic control, receive enhanced screening,
and earlier interventions for disease complications compared with indemnity patients. This pilot study seeks to
evaluate the effectiveness of managed health care initiatives in improving the quality of care for Type 2 diabetes.
In addition, it considers whether differences exist in the
care between capitated and indemnity diabetic patients.
Methods
A five-physician office practice affiliated with a teaching
community hospital in suburban Philadelphia served as
the site of a retrospective chart review. Patients were
identified by billing slips dated from August 1998
through February 1999. A computer audit generated a
list of all patients seen August 1999 through February
2000 with the coded diagnosis of diabetes mellitus,
ICD-9 250.00. Study participants were defined as having diabetes mellitus type 2 if: 1) they exhibited a random blood sugar of >126 mg/dL on more than two

occasions when seen in the primary care office in the
course of one year or 2) they received pharmacologic therapy by chart documentation. Patients were evaluated
based on nine services: weight measurement, microalbumin, blood glucose, lipid panel, treatment of dyslipidemia, angiotensin converting enzyme inhibitor use,
ophthalmologic, podiatry, and nutritionist referrals. The
average weight and blood glucose levels were tabulated.
Intervention with lipid-lowering agents and angiotensin
converting enzyme inhibitor were noted as present or
absent. Referrals to ophthalmology, podiatry, and dietician services were noted as present or absent.
Patients were excluded if they were enrolled in a Preferred
Provider Organization (PPO), Medicare, or Medicare
HMO; changed insurance in less than one year; history of
diabetes mellitus type 1, pancreatitis, glucocorticoid use;
or insufficient documentation for diagnosis.
The data was merged with the statistical program, SPSS.
Statistical analysis used the student’s two-tailed t test to
establish differences between the two groups. Statistical
significance was noted for a p value <0.05.
Results
The cohort comprised 18 capitated and 14 indemnity
patients, and N = number of patient visits. Table 1
reflects demographic data of the patients. The average
age of capitated patients was 55 years while indemnity
patients were 58 years, p value = 0.057. Capitated
patients weighed on average 223 lb. +/- 57 lb. while
indemnity patients weighed 185 lb.+/- 52 lb, p <0.0001.
Glycemic control was evaluated based on the number of
laboratory draws for each group. The average blood glucose for capitated patients was 181+/- 69 mg/dL while
the average blood glucose for indemnity patients was 158
+/- 54 mg/dL; p value = 0.029.
The management of dyslipidemia between the two groups
was noteworthy: although the average total cholesterol of
each group was nearly the same, 23% of indemnity patients
versus 46% of capitated patients were receiving medical
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Table 1. Demographic Data
Age (yrs)
Male
Female
Weight (lb)
SD Weight
Average
Glucose
(mg/dL)
SD (mg/dL)

Capitated
55
9
9
223
47
181

Indemnity
58
2
12
185
52
157

69

54

p value
0.057

treatment (p=0.005). Despite treatment differences, the
data, although not statistically significant, showed a trend
that neither group achieved goal cholesterol <200mg/dL,
LDL <130mg/dL, or LDL < goal 100 mg/dL.

0.0001

The utilization of microalbumin testing was low for both
groups; 7.2% of capitated patients versus 6.7% of indemnity patients were screened; those with positive findings
were under treatment with an angiotensin converting
enzyme inhibitor. Ophthalmology screening revealed
that only 6.7% indemnity patients were referred as
opposed to 20% of capitated patients, p=0.011. Podiatry
and nutrition evaluations revealed a small referral rate
and the difference between the two cohorts was not significant (data not shown).

0.029

Table 2. Cholesterol and LDL Data
Capitated

Indemnity

p value

Average Total Cholesterol
(mg/dL)

218

220

SD (mg/dL)

34

44

0.753

Total Cholesterol Treated
N=# pt visits 32/70

21/90

% tx'd

23%

46%

0.005

Total Cholesterol at Goal <200 mg/dL
N= # pt visits 22/62

24/75

% at goal

36%

32%

0.667

(mg/dL)

136

145

0.142

SD(mg/dL)

31

35

Average LDL

LDL at Goal <130 mg/dL
N=# pt visits 22/51

26/63

% at goal

54%

46%

0.841

LDL at Goal <100 mg/dL
N=# pt visits 6/51

2/47

% at goal

4%

11%

Discussion
The data reveal that capitated patients tended to be more
overweight with inferior glycemic control compared with
indemnity patients. This may reflect gender differences:
nearly all indemnity participants were women while the
capitated patients were equally divided between men and
women. Note that the average blood sugar reflects both
fasting and random values for each group. The more pronounced hyperglycemia in the capitated group may
reflect the higher body mass index and thus, greater
insulin resistance. The capitated group fared better in
decisions for pharmacologic therapy of dyslipidemia as
well as referral to ophthalmology. This may reflect the
practitioner’s lower threshold to screen and treat patients
with an elevated body mass index. However, one would
expect this to extend to other services that diabetics seek,
including screening for nephropathy and recommendation to other health care providers for a multi-specialty
approach to care. Differences were not significant
between the groups in screening for nephropathy, use of
angiotensin converting enzyme inhibitor, or other subspecialty referrals.
This pilot study had several limitations. The number of
patients in each cohort limited meaningful comparisons
between the two groups. Chart reviews are contingent on
the completeness of the practitioner’s notes with treat-

0.175
(Continued on next page)

18
https://jdc.jefferson.edu/tmf/vol3/iss1/9
DOI: https://doi.org/10.29046/TMF.003.004

2

Wagman: A Pilot Study of Diabetes Management in the Managed Care Setting

Original Contribution
(Continued from previous page)

ment plan and follow-up correspondence from the subspecialist. This evaluation did not include duration of
time that the patients were diabetic; newly diagnosed diabetics may not have had the disease of sufficient time to
allow for all referrals and interventions to be examined.
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